These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 34036256)

  • 1. A human liver chimeric mouse model for non-alcoholic fatty liver disease.
    Bissig-Choisat B; Alves-Bezerra M; Zorman B; Ochsner SA; Barzi M; Legras X; Yang D; Borowiak M; Dean AM; York RB; Galvan NTN; Goss J; Lagor WR; Moore DD; Cohen DE; McKenna NJ; Sumazin P; Bissig KD
    JHEP Rep; 2021 Jun; 3(3):100281. PubMed ID: 34036256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication.
    Israelsen M; Kim M; Suvitaival T; Madsen BS; Hansen CD; Torp N; Trost K; Thiele M; Hansen T; Legido-Quigley C; Krag A;
    JHEP Rep; 2021 Oct; 3(5):100325. PubMed ID: 34401690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
    Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
    JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Sowton AP; Padmanabhan N; Tunster SJ; McNally BD; Murgia A; Yusuf A; Griffin JL; Murray AJ; Watson ED
    Mol Genet Metab Rep; 2020 Jun; 23():100580. PubMed ID: 32257815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid alterations in chronic liver disease and liver cancer.
    Paul B; Lewinska M; Andersen JB
    JHEP Rep; 2022 Jun; 4(6):100479. PubMed ID: 35469167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ménage à trois of autophagy, lipid droplets and liver disease.
    Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
    Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
    Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
    Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mechanism of Biejiajian Pills against non-alcoholic steatohepatitis based on lipidomics].
    Huang J; Wang ML; Zhou ZY; Yan T; Xiong H; Mei ZN
    Zhongguo Zhong Yao Za Zhi; 2024 May; 49(10):2557-2565. PubMed ID: 38812156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model.
    Padilla J; Osman NM; Bissig-Choisat B; Grimm SL; Qin X; Major AM; Yang L; Lopez-Terrada D; Coarfa C; Li F; Bissig KD; Moore DD; Fu L
    J Hepatol; 2024 Feb; 80(2):282-292. PubMed ID: 37890720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of hepassocin in the development of non-alcoholic fatty liver disease.
    Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
    J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low HDL-cholesterol levels predict hepatocellular carcinoma development in individuals with liver fibrosis.
    Crudele L; De Matteis C; Piccinin E; Gadaleta RM; Cariello M; Di Buduo E; Piazzolla G; Suppressa P; Berardi E; Sabbà C; Moschetta A
    JHEP Rep; 2023 Jan; 5(1):100627. PubMed ID: 36561127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis.
    Schröder T; Kucharczyk D; Bär F; Pagel R; Derer S; Jendrek ST; Sünderhauf A; Brethack AK; Hirose M; Möller S; Künstner A; Bischof J; Weyers I; Heeren J; Koczan D; Schmid SM; Divanovic S; Giles DA; Adamski J; Fellermann K; Lehnert H; Köhl J; Ibrahim S; Sina C
    Mol Metab; 2016 Apr; 5(4):283-295. PubMed ID: 27069868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease.
    Tang Y; Bian Z; Zhao L; Liu Y; Liang S; Wang Q; Han X; Peng Y; Chen X; Shen L; Qiu D; Li Z; Ma X
    Clin Exp Immunol; 2011 Nov; 166(2):281-90. PubMed ID: 21985374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A metabolomic analysis of omega-3 fatty acid-mediated attenuation of western diet-induced nonalcoholic steatohepatitis in LDLR-/- mice.
    Depner CM; Traber MG; Bobe G; Kensicki E; Bohren KM; Milne G; Jump DB
    PLoS One; 2013; 8(12):e83756. PubMed ID: 24358308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysosomal Acid Lipase Activity in Non-alcoholic Fatty Liver Disease as a Novel Diagnostic and Therapeutic Target: A Systematic Literature Review of Current Evidence and Future Directions.
    Bashir A; Duseja A; Verma A; De A; Tiwari P
    J Clin Exp Hepatol; 2022; 12(6):1535-1546. PubMed ID: 36340307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
    Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
    Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
    Majdi A; Aoudjehane L; Ratziu V; Islam T; Afonso MB; Conti F; Mestiri T; Lagouge M; Foufelle F; Ballenghien F; Ledent T; Moldes M; Cadoret A; Fouassier L; Delaunay JL; Aït-Slimane T; Courtois G; Fève B; Scatton O; Prip-Buus C; Rodrigues CMP; Housset C; Gautheron J
    J Hepatol; 2020 Apr; 72(4):627-635. PubMed ID: 31760070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.